Information Provided By:
Fly News Breaks for April 20, 2016
MNK
Apr 20, 2016 | 08:34 EDT
After hosting a call featuring a rheumatologist who runs a clinic focused on the treatment of patients with lupus, Piper Jaffray analyst David Amsellem says he continues to believe that visibility on sustained volume growth for Mallinckrodt's Acthar is strong. The rheumatologist's commentary on Acthar, particularly regarding its role in lupus, was favorable, Amsellem tells investors in a research note. The analyst thinks Mallinckrodt is well-positioned to deliver long-term annual earnings growth potentially in the low double-digits. He views the current valuation of Mallinckrodt as attractive and keeps an Overweight rating on the shares with a $97 price target.
News For MNK From the Last 2 Days
There are no results for your query MNK